Annual lung function changes in young patients with chronic lung disease

Reference equations for ventilatory function that use different statistical models may introduce artifacts that affect the estimated change of lung function during growth in young subjects. The effect of differently modelled reference equations on the estimated annual change of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) in young patients with chronic lung disease was assessed. Four frequently used reference equations were used to describe the longitudinal changes of FEV1 and FVC in 52 patients (23 females) with cystic fibrosis (CF) during a mean follow-up of 3.9 yrs. Choice of reference equations directly affected value and, most importantly, estimated annual change of FVC and FEV1. Mean±sd annual change of FEV1 varied from 2.2±6.2 to −2.2±3.6% of predicted. For two reference equations the estimated individual changes of FEV1 and FVC in CF were positively correlated with mean individual age. This probably reflects underestimation of deteriorating lung function. Variability of annual change was independent of age only when reference equations that were designed to accurately predict lung function during the pubertal growth spurt were used. These findings have implications for patient care and clinical research.

[1]  Marsha A. Elkhunovich,et al.  Pulmonary , 2020, Modern Pathology.

[2]  H. Weill,et al.  Noncomparability of longitudinally and cross-sectionally determined annual change in spirometry. , 2015, American Review of Respiratory Disease.

[3]  J. Emerson,et al.  Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients * , 2001, Pediatric pulmonology.

[4]  T. Hazinski Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. , 1999, The Journal of pediatrics.

[5]  B. Brunekreef,et al.  Spirometric reference values for white European children and adolescents: Polgar revisited , 1995, Pediatric pulmonology.

[6]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[7]  A. Kamada EFFECT OF 22 MONTHS OF TREATMENT WITH INHALED CORTICOSTEROIDS AND/OR BETA-2- AGONISTS ON LUNG FUNCTION, AIRWAY RESPONSIVENESS, AND SYMPTOMS IN CHILDREN WITH ASTHMA , 1994, Pediatrics.

[8]  P. J. Byard The adolescent growth spurt in children with cystic fibrosis. , 1994, Annals of human biology.

[9]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[10]  M. Hughes,et al.  Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. , 1992, The American review of respiratory disease.

[11]  J. Stocks,et al.  Compilation of reference values for lung function measurements in children. , 1989, The European respiratory journal. Supplement.

[12]  P. Quanjer,et al.  Changes in the FEV1-height relationship during pubertal growth. , 1984, Bulletin europeen de physiopathologie respiratoire.

[13]  M. Lebowitz,et al.  Changes in the normal maximal expiratory flow-volume curve with growth and aging. , 1983, The American review of respiratory disease.

[14]  E. Pattishall,et al.  Noncomparability of cross‐sectional and longitudinal estimates of lung growth in children , 1989, Pediatric pulmonology.